Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia

Eur J Haematol. 2002 Sep;69(3):171-8. doi: 10.1034/j.1600-0609.2002.02785.x.


Resistance to cytarabine (AraC) is a major problem in treatment of patients with acute myeloid leukemia (AML). In contrast to in vitro AraC resistance, deoxycytidine kinase (dCK) mutations are rarely found in patients with refractory or relapsed AML. Previously we have demonstrated alternatively spliced dCK mRNA predominantly expressed in leukemic blasts from patients with resistant AML. In this study we investigated wild-type (wt) dCK expression and activity to elucidate the possible role of decreased dCK expression or activity in unresponsiveness to AraC in patients with AML. No alterations in dCK mRNA and protein expression or in dCK activity were detected between patients with clinically resistant vs. sensitive AML. In addition, wt dCK expression and activity were not reduced in leukemic blasts expressing alternatively spliced dCK forms as compared to blasts with only wt dCK. Also, no major differences in wt dCK expression and activity were observed between samples obtained from patients with AML and bone marrow or peripheral blood samples from healthy donors. These data implicate that in our patient group of refractory or relapsed AML cases, alterations in dCK expression and/or activity cannot explain unresponsiveness to chemotherapy including AraC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Antimetabolites, Antineoplastic / therapeutic use
  • Cytarabine / therapeutic use
  • Deoxycytidine Kinase / genetics
  • Deoxycytidine Kinase / metabolism*
  • Drug Resistance, Neoplasm / genetics
  • Enzyme Activation
  • Humans
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / enzymology*
  • Recurrence


  • Antimetabolites, Antineoplastic
  • Cytarabine
  • Deoxycytidine Kinase